Trefoil Factor 3 Predicts Incident Chronic Kidney Disease: A Case-Control Study Nested within the Atherosclerosis Risk in Communities (ARIC) StudyAstor B.C.a–c · Köttgen A.b, d · Hwang S.-J.e · Bhavsar N.a, b · Fox C.S.e, f · Coresh J.a–c, g
aWelch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, bDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, and cDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Md., USA; dRenal Division, University Hospital Freiburg, Freiburg, Germany; eNational Heart, Lung and Blood Institute’s Framingham Heart Study and the Center for Population Studies, Bethesda, Md. and Framingham, Mass., fDivision of Endocrinology, Hypertension, and Metabolism, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass., and gDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md., USA Corresponding Author
Brad Astor, PhD, MPH
Departments of Epidemiology and Medicine, Johns Hopkins University
2024 East Monument Street, Suite 2-600
Baltimore, MD 21287 (USA)
Tel. +1 410 502 2779, E-Mail firstname.lastname@example.org
Background: Early detection of individuals at high risk for chronic kidney disease (CKD) may aid prevention. Urinary levels of trefoil factor 3 (TFF3) are associated with acute kidney injury in animal models, but the association of TFF3 levels with incident CKD in humans is unknown. Methods: We conducted a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) Study and the ARIC Carotid MRI Study to determine whether urinary TFF3 levels predict incident CKD over 8.6 years of follow-up. A total of 143 participants with incident CKD (eGFR decreasing by ≧25% to <60 ml/min/1.73 m2) were matched on age, sex and race to 143 non-cases. Results: Higher TFF3 levels at baseline were strongly associated with Black race, diabetes (both p = 0.002), and antihypertensive medication use (p = 0.02). Compared to participants with TFF3 levels in the lowest quartile, the odds ratio (OR) of incident CKD was 1.84 (95% confidence interval (CI): 0.80, 4.22) for individuals with TFF3 levels in the second quartile, 2.43 (95% CI: 1.06, 5.53) for the third quartile, and 2.77 (95% CI: 1.22, 6.28) for the fourth quartile (p trend = 0.02). Adjustment for covariates, including urinary albumin: creatinine ratio, did not markedly change the associations. Twofold higher TFF3 levels were strongly associated with incident CKD after adjustment for CKD risk factors (adjusted OR = 1.35; 95% CI: 1.11, 1.64). Conclusions: Higher urinary TFF3 levels may indicate ongoing repair of damage in the kidney. Additional studies are needed to confirm whether TFF3 can be useful as a marker of increased risk for CKD.
© 2011 S. Karger AG, Basel
Chronic kidney disease (CKD) is associated with an elevated risk of cardiovascular disease, end-stage renal disease, and mortality, even at moderately decreased levels of glomerular filtration rate (GFR) [1,2,3]. Recent research has focused on factors associated with the progression of existing CKD [4,5,6,7], with relatively few studies investigating predictors of incident CKD [8,9,10]. Early detection of individuals at increased risk of developing CKD may allow timely initiation of measures to prevent CKD and its complications . Current measures of kidney function (e.g., GFR estimated from serum creatinine) and kidney damage (e.g., urinary excretion of albumin) used to diagnose CKD are imprecise and may be insensitive to mildly impaired kidney function or damage [7,12]. The identification of new markers may allow improved prediction of CKD risk, better targeting of patients for risk-reducing therapies, and potentially a better understanding of the pathophysiologic processes leading to CKD.
In 2008, the US Food and Drug Administration (FDA) and its European counterpart, the European Medicines Evaluation Agency (EMEA), through the Critical Path Initiative , jointly accepted seven urinary biomarkers for use in non-clinical drug development as indicators of acute drug-induced kidney toxicity. Among these biomarkers is trefoil factor 3 (TFF3), also known as intestinal trefoil factor (ITF), a peptide which is expressed in goblet cells of the intestines, colon and kidney . Although the function of TFF3 has not been fully characterized, the members of the trefoil family play an integral role in the protection and repair of the gastrointestinal mucosa. Urinary levels of TFF3 are associated with acute kidney injury in animal models . It is unknown, however, whether urinary levels are associated with incident CKD in humans.
We tested whether urinary levels of TFF3 are associated with incident CKD among individuals without decreased GFR or albuminuria in a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) Study and the ARIC Carotid MRI Study.
The ARIC Study is a prospective biracial observational cohort of 15,792 individuals, recruited from a probability sample of four US communities (Forsyth County, N.C.; Jackson, Miss.; suburban Minneapolis, Minn., and Washington County, Md., USA). Participants took part in clinic examinations, starting with a baseline visit during 1987–89, at which time participants were 45–64 years of age, and including three follow-up examinations at approximately 3-year intervals, during which carotid artery intima-media thickness (IMT) was measured using B-mode ultrasound . We used ARIC Exam 4, conducted in 1996–98, as the baseline visit for this case-control analysis, as this was the first visit at which urine specimens were collected. A total of 11,656 participants attended ARIC Exam 4.
The ARIC Carotid MRI Study examination served as the follow-up visit for this case-control analysis. Participants for the ARIC Carotid MRI Study were selected in 2004–05 from the surviving ARIC Study participants under a stratified sampling plan, based on the most recent IMT and field center . The goal was to recruit 1,200 participants with high values of maximum carotid artery IMT at their most recent ultrasound examination (ARIC Exam 3 or 4, 1993–95 or 1996–98) and 800 individuals randomly sampled from the remaining eligible participants. A total of 4,306 persons were invited: 1,403 refused, 837 were ineligible, and 2,066 participated.
Cases and controls were selected from ARIC participants with data on serum creatinine at both ARIC Exam 4 (baseline) and the ARIC Carotid MRI Study visit (follow-up). Participants with an estimated GFR (eGFR) <60 ml/min/1.73 m2 or a urinary albumin:creatinine ratio (ACR) ≥30 mg/g at baseline were excluded. Cases of incident CKD were identified as those participants with an eGFR <60 ml/min/1.73 m2 at follow-up and a decrease in eGFR from baseline to follow-up of ≥25% . Controls were frequency matched to cases by race, sex, and 5-year age categories.
Measurement of TFF3 was conducted using an immunoassay on a bead Luminex platform (Rules Based Medicine, Austin, Tex., USA) after centrifugation at 4,000 rpm for 5 min. The assay for TFF3 has an interassay coefficient of variation of 12% at a mean concentration of 0.3 µg/ml and 13% at a mean concentration of 12 µg/ml. Eight participants (5 cases and 3 controls) had TFF3 levels below the limit of detection and these values were set 0.064 µg/ml, the lowest value measured among ARIC participants.
A modified kinetic Jaffé method was used to measure serum creatinine and the abbreviated Modification of Diet in Renal Disease (MDRD) Study equation was used to estimate GFR [19,20]. The creatinine concentration for ARIC Visit 4 values was corrected for interlaboratory differences and indirectly calibrated to the Cleveland Clinic measurement by the addition of 0.18 mg/dl [19,20]. Creatinine concentrations measured at the ARIC Carotid MRI Study visit were IDMS traceable. Spot urine samples were collected and stored at –70°C. Urinary albumin levels were measured by nephelometry and urinary creatinine levels were measured using the Jaffé method.
Systolic and diastolic blood pressures were measured following 5 min of rest. Three seated measurements were taken by certified technicians using a random-zero sphygmomanometer. The average of the second and third readings was recorded. Diabetes mellitus was defined as a fasting glucose of ≥126 mg/dl, non-fasting glucose of ≥200 mg/dl, use of oral hypoglycemic medication or insulin, or self-reported physician diagnosis of diabetes mellitus. Plasma cholesterol, triglycerides and high-density lipoprotein cholesterol were determined using enzymatic methods, and low-density lipoprotein cholesterol was calculated using the Friedewald equation . Body mass index (BMI) was calculated as weight [kg]/height [m]2. Current smoking status and race were defined by self-report.
Levels of TFF3 and covariates were compared between cases and controls with t tests or χ2 tests, as appropriate. Pearson correlation coefficients were calculated for TFF3 with the other covariates. The concentrations of TFF3 and ACR were skewed and were therefore natural log-transformed to achieve approximate normality for continuous analyses. The association between the log-transformed values of TFF3 and case status was examined continuously and by quartiles. A logistic regression cubic spline model with knots at the 25, 50 and 75th percentiles was used to assess the continuous relationship between TFF3 and incident CKD. This model was adjusted for age (55 years) and sex (female) for graphical presentation. Conditional logistic regression was used to calculate unadjusted and adjusted odds ratios (OR) associated with twofold higher TFF3. Adjustment was performed for systolic blood pressure, use of antihypertensive medication, diabetes, current smoking, BMI, high density lipoprotein cholesterol, triglycerides, eGFR, log of ACR, and the ARIC Carotid MRI Study sampling variables of center and IMT strata. Deviation from non-linearity was assessed with likelihood ratio tests comparing a linear model to models including 2nd, 3rd, 4th and 5th order polynomials. Analyses were repeated after stratifying by sex, race and diabetes. Analyses also were repeated for the ratio of urinary TFF3 to urinary creatinine. Statistical analyses were conducted using STATA, version 10 (StataCorp, College Station, Tex., USA).
A total of 143 cases were identified and matched to 143 controls. The mean age of the participants was 64.7 years at baseline (table 1). Approximately 53% were female and 22% were Black. Cases had a higher mean systolic blood pressure, BMI and triglycerides than controls. The prevalence of diabetes (18.4% in cases, 14.7% in controls; p = 0.43) and urinary ACR levels (median = 3.4 mg/g in cases and 3.1 mg/g in controls; p = 0.62) at baseline did not differ significantly by case status. The mean eGFR at baseline also did not differ significantly between cases (81.6 ml/min/1.73 m2) and controls (83.2 ml/min/1.73 m2).
The median TFF3 level was 0.55 µg/ml (interquartile range: 0.27–1.10). Higher TFF3 levels were strongly associated with Black race and diabetes (both p = 0.002; table 2). Higher TFF3 levels also were associated with antihypertensive medication use (p = 0.02). Participants in the lowest TFF3 quartile were much more likely to be female than those with higher TFF3 levels. Higher TFF3 quartiles remained associated with each of these variables after adjustment for the others (all p ≤ 0.05).
Median TFF3 levels were significantly higher in cases (0.7 µg/ml) than in controls (0.5 µg/ml; p = 0.005) (fig. 1). Compared to participants with TFF3 levels in the lowest quartile, the OD of incident CKD was 1.84 (95% confidence interval (CI): 0.80, 4.22) for individuals with TFF3 levels in the second quartile, 2.43 (95% CI: 1.06, 5.53) for the third quartile, and 2.77 (95% CI: 1.22, 6.28) for the fourth quartile (p trend = 0.02; table 3). Adjustment for covariates strengthened these associations slightly (p trend = 0.01). Further adjustment for urinary ACR did not markedly change the associations (p trend = 0.02).
The continuous relationship between TFF3 and incident CKD is shown in figure 2. Higher TFF3 was associated with a greater probability of being a case in a log-linear manner (p = 0.25 for deviation from linearity). Twofold higher TFF3 was associated with a 29% (95%CI: 8%, 54%) higher odds of developing incident CKD (table 4). As for the categorical analyses, adjustment for covariates strengthened the association slightly. The OD was similar in a model adjusting for diabetes, current smoking, BMI, high-density lipoprotein cholesterol, triglycerides, and eGFR (OR = 1.35; 95% CI: 1.10, 1.63). Further adjustment for log ACR did not change the OR (p = 0.003).
The association between the ratio of urinary TFF3 to urinary creatinine and incident CKD were somewhat weaker. After full adjustment, each twofold higher urinary TFF3:creatinine was associated with an adjusted OR of 1.22% (95% CI: 0.97, 1.53%) for incident CKD.
Twofold higher TFF3 was significantly associated with incident CKD in analyses limited to males (adjusted OR = 1.45; 95% CI: 1.03, 2.04) or females (adjusted OR = 1.33; 95% CI: 1.02, 1.75). The OR associated with twofold higher TFF3 did not differ significantly between Whites (adjusted OR = 1.38; 95% CI: 1.11, 1.72) and Blacks (adjusted OR = 1.71; 95% CI: 0.78, 3.73), or between those with diabetes (adjusted OR = 1.29; 95% CI: 1.04, 1.60) and those without diabetes (adjusted OR = 1.07; 95% CI: 0.43, 2.64), though power was limited for these analyses.
In this matched case-control study, higher TFF3 was strongly associated with incident CKD over a median follow-up of 8.6 years. Baseline TFF3 levels were higher among Blacks, females, individuals with diabetes and those using antihypertensive medications. Higher TFF3 remained significantly associated with incident CKD after adjustment for these factors, as well as for other CKD risk factors, including urinary albumin excretion.
TFF3 is a member of the trefoil factor family (TFF; consisting of TFF 1, TFF 2 and TFF 3), peptides which are secretory products of a variety of mucin-producing epithelial cells, including the gastrointestinal tract . These peptides play a crucial role in the defense and repair of the mucosa through numerous mechanisms, including formation of mucous barriers, rapid repair by cell migration (‘restitution’), antiapoptopic effects, and modulation of differentiation and immune response and inflammatory processes . Pathologic expression of TFF peptides has been observed during a variety of chronic inflammatory diseases and certain tumors [24,25]. TFF3 has been accepted by the FDA and the EMEA as a biomarker of drug-induced acute kidney tubular alterations in rat studies used to support clinical trials . This decision was based on changes in urine TFF3 levels in rats with 2 weeks of drug-induced nephrotoxicity.
Recent experiments in humans have found TFFs synthesized throughout the urinary tract, with TFF3 being the predominate TFF in cells of the proximal and distal tubules and collecting duct . Synthesis of TFF3 was found primarily in the basal and intermediate layers. The authors hypothesized that TFF3 may be partly responsible for the regenerative capacity of the kidney, possibly through restitution, which is initiated very quickly after injury [27,28,29], and/or effects on differentiation, which takes place over a longer time period [30,31,32]. Others have hypothesized similar roles for TFF3 in the gastric antrum [32,33].
The role of TFF3 in CKD is unknown. We speculate that TFF3 is involved in the repair of injury, presumably to the tubular epithelium, and that the higher levels observed in the urine are indicative of ongoing repair, which, in turn, is indicative of damage or ongoing inflammatory processes. If this hypothesis is correct, TFF3 may be useful as a marker of CKD risk. Levels of TFF3 were much higher in participants with diabetes and in participants using antihypertensive medications than in their counterparts. The reasons for these differences are unknown. Diabetes and hypertension are potent risk factors for CKD , and these differences may provide additional evidence that TFF3 levels are associated with ongoing kidney damage. The lack of an association between TFF3 and urinary ACR argues against this hypothesis, but the restricted range of ACR values in these studies limits our ability to fully explore this potential association. The reasons for higher levels among Blacks compared to Whites and women compared to men are unknown.
This study has several limitations, including the use of a case-control design, which excludes individuals that died or were lost to follow-up or were ineligible for the follow-up examination. Any systematic bias, however, would likely attenuate the observed association. The relatively small sample size provided limited power for investigating associations within various subgroups, such as by diabetes status. The relative small sample size does not preclude statistical chance as an explanation for this difference. The definition of incident CKD (i.e., follow- up eGFR <60 ml/min/1.73 m2 and a ≥25% decrease in eGFR) was based on a single serum creatinine measurement at each visit, which can be imprecise. The case definition, therefore, may not detect significant changes in kidney function, or may detect clinically insignificant decreases [18,19]. Again, any imprecision would likely result in observing attenuated associations. This is a pilot study, and the observed associations should be explored in larger studies.
In conclusion, we found that higher urinary levels of TFF3 were associated with incident CKD. If confirmed in additional studies, TFF3 may be useful as a marker of future risk of CKD.
The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022 with the ARIC carotid MRI examination funded by U01HL075572-01. The ARIC sample assays were supported by the National Institute of Diabetes and Digestive and Kidney Diseases (1 R01 DK076770-01). The authors thank the staff and participants of the ARIC Study for their important contributions.
Brad Astor, PhD, MPH
Departments of Epidemiology and Medicine, Johns Hopkins University
2024 East Monument Street, Suite 2-600
Baltimore, MD 21287 (USA)
Tel. +1 410 502 2779, E-Mail email@example.com
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.